Churg-Strauss syndrome classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 32: Line 32:


==Classification==
==Classification==
*According to the 1994 Chapel Hill consensus conference nomenclature of vasculitides, Eosinophilic granulomatosis with polyangiitis is described as an eosinophil-rich and granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis involving small to medium-sized arteries and venules, associated with asthma and eosinophilia.
*The eponym Churg–Strauss syndrome, has been replaced during the 2012 Revised International Chapel Hill consensus conference, by mainly focusing on the histopathology of the disease. Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss' syndrome) can be considered a variant of the ANCA associated vasculitides of the small vessels.<ref name="pmid23045170">{{cite journal |vauthors=Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA |title=2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides |journal=Arthritis Rheum. |volume=65 |issue=1 |pages=1–11 |date=January 2013 |pmid=23045170 |doi=10.1002/art.37715 |url=}}</ref>
*The Revised International Chapel Hill Consensus Conference 2012 has stated that ANCA are found in eosinophilic granulomatosis with polyangiitis, particularly in patients with glomerulonephritis. This may suggest some of the new evidence of the distinction of EGPA subsets, depending on the presence or the absence of ANCA.
*The Chapel Hill Consensus Conference, however, does not propose any diagnostic or classification criteria.
*Therefore, the diagnostic criteria proposed by the American College of Rheumatology (ACR) in 1990 on Eosinophilic granulomatosis with polyangiitis is still being used to distinguish the disease. The presence of 4 out of the 6 diagnostic criteria has a reported sensitivity of 85% and a specificity of 99.7% for the diagnosis of Eosinophilic granulomatosis with polyangiitis.
{| class="wikitable"
!American College of Rheumatology (ACR) Classification of Eosinophilic granulomatosis with polyangiitis
|-
|Asthma
|-
|Eosinophilia > 10%
|-
|Neuropathy (mononeuropathy or polyneuropathy)
|-
|Pulmonary infiltrate, non fixed
|-
|Paranasal sinus abnormality
|-
|Biopsy that shows extravascular eosinophil infiltration
|}


*There is no established system for the classification of [disease name].
*There is no established system for the classification of [disease name].

Revision as of 19:16, 29 March 2018

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome classification

CDC on Churg-Strauss syndrome classification

Churg-Strauss syndrome classification in the news

Blogs on Churg-Strauss syndrome classification

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [3]

Overview

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

  • According to the 1994 Chapel Hill consensus conference nomenclature of vasculitides, Eosinophilic granulomatosis with polyangiitis is described as an eosinophil-rich and granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis involving small to medium-sized arteries and venules, associated with asthma and eosinophilia.
  • The eponym Churg–Strauss syndrome, has been replaced during the 2012 Revised International Chapel Hill consensus conference, by mainly focusing on the histopathology of the disease. Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss' syndrome) can be considered a variant of the ANCA associated vasculitides of the small vessels.[1]
  • The Revised International Chapel Hill Consensus Conference 2012 has stated that ANCA are found in eosinophilic granulomatosis with polyangiitis, particularly in patients with glomerulonephritis. This may suggest some of the new evidence of the distinction of EGPA subsets, depending on the presence or the absence of ANCA.
  • The Chapel Hill Consensus Conference, however, does not propose any diagnostic or classification criteria.
  • Therefore, the diagnostic criteria proposed by the American College of Rheumatology (ACR) in 1990 on Eosinophilic granulomatosis with polyangiitis is still being used to distinguish the disease. The presence of 4 out of the 6 diagnostic criteria has a reported sensitivity of 85% and a specificity of 99.7% for the diagnosis of Eosinophilic granulomatosis with polyangiitis.
American College of Rheumatology (ACR) Classification of Eosinophilic granulomatosis with polyangiitis
Asthma
Eosinophilia > 10%
Neuropathy (mononeuropathy or polyneuropathy)
Pulmonary infiltrate, non fixed
Paranasal sinus abnormality
Biopsy that shows extravascular eosinophil infiltration
  • There is no established system for the classification of [disease name].

OR

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
    • [Group1]
    • [Group2]
    • [Group3]
    • [Group4]

OR

  • [Disease name] may be classified into [large number > 6] subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]
  • [Disease name] may be classified into several subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]

OR

  • Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

  • If the staging system involves specific and characteristic findings and features:
  • According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

  • The staging of [malignancy name] is based on the [staging system].

OR

  • There is no established system for the staging of [malignancy name].

References

  1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (January 2013). "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides". Arthritis Rheum. 65 (1): 1–11. doi:10.1002/art.37715. PMID 23045170.

Template:WH Template:WS